Copay estimates, coupon programs, accumulator rules, and 340B Drug Pricing Program cash-pay encounters could all be touched, especially for chronic primary-care therapies where patients feel every dollar in their monthly totals.²,³ Until official notices arrive, pharmacists should set expectations clearly: savings mechanisms may roll out in stages; eligibility will be plan-specific; and clinicians will need to match patients to the correct channel, traditional benefit, manufacturer support, or any new direct-purchase option, without compromising continuity of care.²,³A Companion Development: AI for Pediatric OncologyOn the same date, the White House announced an executive order aimed at scaling the use of AI in pediatric cancer research and care. How was it validated (external sites, prospective cohorts)? How are bias, equity, and safety monitored over time? And how exactly do outputs affect dosing, trial eligibility, adverse-event prediction, or supportive-care pathways inside electronic health records (EHRs)?⁴,⁶ These are not academic footnotes; they are the scaffolds that keep enthusiasm from outpacing evidence in a population where margins for error are razor thin. Defining Terms and Guarding Against ShortcutsAbbreviations such as artificial intelligence (AI), most-favored nation (MFN) pricing, National Cancer Institute (NCI), and the Childhood Cancer Data Initiative (CCDI) should be introduced with care.